Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Total Debt (2016 - 2026)

Ekso Bionics Holdings has reported Total Debt over the past 13 years, most recently at $2.8 million for Q4 2025.

  • On a quarterly basis, Total Debt fell 27.19% to $2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a 27.19% decrease, with the full-year FY2025 number at $2.8 million, down 27.19% from a year prior.
  • Total Debt reached $2.8 million in Q4 2025 per EKSO's latest filing, down from $3.0 million in the prior quarter.
  • The five-year high for Total Debt was $5.1 million in Q3 2023, with the low at $2.0 million in Q2 2021.
  • The 5-year median for Total Debt is $3.3 million (2025), against an average of $3.3 million.
  • Peak YoY movement for Total Debt: tumbled 35.3% in 2021, then soared 89.01% in 2022.
  • Tracing EKSO's Total Debt over 5 years: stood at $2.0 million in 2021, then soared by 89.01% to $3.8 million in 2022, then increased by 28.27% to $4.8 million in 2023, then fell by 20.24% to $3.9 million in 2024, then dropped by 27.19% to $2.8 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $2.8 million, $3.0 million, and $3.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.